CD274 and non-small cell lung carcinoma: In addition, a meta-analysis of 22 clinical trials with single PD-1 or PDL-1 inhibitors in NSCLC (pembrolizumab, nivolumab, and atezolizumab) suggested a 5.2% overall rate of significant cardiac events during a brief follow-up period with 1.0% for fatal MI [51].